Cancer Vaccines

Excerpt from Custom Post Type Indication: CVAC

ASCO 2026 Analyst Briefing: Webinar

Executive Summary: ONCrg analysts Robert Williams and Amanda Cook preview the highest-impact clinical presentations at ASCO 2026 across pancreatic, non-small cell lung, prostate, multiple myeloma, and NHL — covering the context of each readout, how the treatment landscape is expected to shift, and the specific signals the analyst team will be watching for on the floor.

ONCrg Congress Insights: 
MPNs at ASCO/EHA 2026 and Beyond

Potential game changers: Late-stage readouts at ASCO/EHA: Selinexor: The last of the wave of novel MOA + ruxolitinib pivotal trials in frontline myelofibrosis (MF). All in this wave have faced struggles, selinexor included, with a missed symptom endpoint in Phase III SENTRY. Detailed outcomes reported at ASCO will inform not only the next steps for selinexor, but future development in the field of first-line MF as a whole.

ASCO 2026 Analyst Briefing

MPNs at ASCO/EHA 26

Oncology Momentum: Tracking the Early Pipeline from AACR to ASCO – Transcript

Emerging Clinical Signals

Excerpt from Custom Post Type Indication: ECS

Antibody Drug Conjugates

Medical Conference Coverage EHA: June 11-14, 2026 WCLC: September 12-15, 2026 ESMO: October 23-27, 2026 SNO: November 12-15, 2026 SABCS: December 8-11, 2026 ASH: December 12-15, 2026  ASCO GU: February 11-13, 2027 ELCC: March 17-20, 2027 SGO: March 19-22, 2027 AACR: April 2-7, 2027 ASCO: June 4-8, 2027 ICML: June 15-19, 2027 Antibody-Drug Conjugates (ADCs) […]

DNA Damage Response

The DNA damage response (DDR) field has seen major advances in recent years, particularly in ovarian, breast, prostate, and pancreatic cancers. Most cancers depend on DNA damage detection and repair for survival and are thus vulnerable to targeted inhibition of DDR proteins. DDR therapies include inhibitors of PARP, ATR, WEE1, and DNA-PK. The DDR field […]

Non-Hodgkin’s Lymphoma

Excerpt from Custom Post Type Indication: NHL